Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SAR447998 phase 1/2 study in refractory systemic lupus erythematosus or rheumatoid arthritis
2026-526117-28-00Phase 2Authorised
- Sponsor
- Sanofi
- Start
- Oct 2026
- Countries
- 4
01
Overview
Phase 2 trial of SAR447998 in systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA), sponsored by Sanofi. Planned start Oct 2026; status: authorised.
02
Drugs
SAR447998
03
Conditions
systemic lupus erythematosus (SLE)rheumatoid arthritis (RA)
Beyond the preview
Go deeper on 2026-526117-28-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2026-526117-28-00.